Clinical Trial Update: Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial assessed bortezomib with or without gemcitabine for metastatic pancreatic cancer (pancreatic ductal adenocarcinoma) and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Bortezomib (bortezomib)
• Gemzar (gemcitabine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer | Phase 2 | Status: COMPLETED